Executive Summary
Three mega contracts totaling $1,236,299,978 in obligations were analyzed, with 1/3 defense-related (~$412M) and 2/3 civilian (~$824M), dominated by civilian IT services awards to Leidos ($543.6M GSA) and Oracle Health ($519M VA).
The highest-conviction bullish signal is Oracle Health Government Services' $518.9M VA EHRM delivery order (strength 7/10, materiality 8/10), signaling stable multi-year backlog in VA IT amid no outlays to date. Leidos' GSA IT contract adds $543.6M funded backlog nearing end in 2024, while BL Harbert's $173.7M State construction remains neutral. Key risk is $0 outlays on Oracle and BL Harbert contracts, plus Leidos' negative $-1.7M outlay, warranting watches on spending progress and option exercises.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from April 10, 2026.
Investment Signals (3)
- Oracle Health Secures $519M VA EHRM Delivery Order (HIGH)▲
Oracle Health Government Services, Inc. received a $518,959,505 obligated firm fixed price delivery order from VA (potential $632.8M with options) for EHRM operations under NAICS 541512, not competed, spanning 2022-2027 with $0 outlayed to date.
- Leidos Lands $544M GSA IT Services Delivery Order (MEDIUM)▲
Leidos, Inc. awarded $543,645,833 cost-plus award fee delivery order from GSA (potential $729.6M with options) for IT/telecom integrated services under full and open competition, running through 2024 with $187.4M subawards but negative $-1.7M outlay.
- BL Harbert Wins $174M State Dept Construction Contract (LOW)▲
BL Harbert International LLC received $173,694,639 firm fixed price contract from Department of State for Podgorica Montenegro project under full and open competition, spanning 2019-2027 with $0 outlayed and $5.5M subawards.
Risk Flags (2)
- Execution [HIGH RISK]▼
Oracle Health and BL Harbert contracts show $0 outlays to date despite $518.9M and $173.7M obligations, with high firm fixed price risk; Leidos has negative $-1.7M outlay on $543.6M GSA award.
- Budget [MEDIUM RISK]▼
Unexercised options on Leidos ($729.6M potential) and Oracle ($632.8M potential) represent upside risk if not funded amid civilian agency CR uncertainty.
Opportunities (2)
- ◆
Oracle Health's $632.8M potential VA IT delivery order offers multi-year EHRM backlog through 2027-04-10.
- ◆
Leidos' $729.6M potential GSA IT order provides funded backlog extension if options exercised before 2024-02-29 end.
Sector Themes (2)
- ◆
Leidos ($543.6M GSA) and Oracle Health ($518.9M VA) delivery orders under NAICS 541512 total over $1B in civilian IT obligations, with cost-plus and firm fixed structures signaling demand for integrated IT/telecom and EHRM support.
- ◆
BL Harbert's $173.7M firm fixed price award for Montenegro project (PSC C215) under full competition highlights steady diplomatic construction spend through 2027.
Watch List (3)
- 👁
{"entity"=>"Oracle Health Government Services, Inc.", "reason"=>"$518.9M VA obligation with $0 outlay and $632.8M option potential under firm fixed price.", "trigger"=>"outlay progress and option exercise by 2027-04-10"}
- 👁
{"entity"=>"Leidos, Inc.", "reason"=>"$543.6M GSA obligation with negative $-1.7M outlay nearing 2024-02-29 end and $729.6M option ceiling.", "trigger"=>"outlay reversal and option exercises before 2024-02-29"}
- 👁
{"entity"=>"BL Harbert International LLC", "reason"=>"$173.7M State Dept contract with $0 outlay across 7.5-year period.", "trigger"=>"outlay initiation toward 2027-03-25 end date"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Mega Contracts Monitor ($100M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals